<p>Tenax Therapeutics, Inc.（纳斯达克代码：TENX - 获取免费报告）内部人士 Stuart Rich 于 12 月 4 日星期四购买了 2,500 股该公司的股票。每股平均购买价格为 9.20 美元，总交易额为 23,000.00 美元。交易完成后，该内部人士直接持有 2,500 股公司股票，价值 23,000 美元。这笔交易代表了他们对该股票的持有量增加了∞。该交易已在向 SEC 提交的文件中披露，文件可通过此链接获取。</p>
<p>Stuart Rich 最近还进行了以下交易：</p>
<ul>
<li>在 12 月 3 日星期三，Stuart Rich 购买了 1,500 股 Tenax Therapeutics 的股票。股票的平均购买价格为每股 9.08 美元，总价值为 13,620.00 美元。</li>
<li>在 12 月 2 日星期二，Stuart Rich 收购了 1,000 股 Tenax Therapeutics 的股票。每股平均购买价格为 9.01 美元，总交易额为 9,010.00 美元。</li>
</ul>
<p>获取 <strong>Tenax Therapeutics</strong> 的提醒：</p>
<h2>Tenax Therapeutics 股价上涨 3.2%</h2>
<p>在周五的午盘交易中，TENX 的股价上涨了 0.30 美元，达到了 9.65 美元。该股票的交易量为 168,431 股，而其平均交易量为 50,192 股。该公司的 50 日简单移动平均线为 7.66 美元，200 日简单移动平均线为 6.58 美元。该公司的市值为 6025 万美元，市盈率为-8.54，贝塔值为 1.55。Tenax Therapeutics, Inc.的 52 周最低价为 4.63 美元，52 周最高价为 9.91 美元。</p>
<p>Tenax Therapeutics（纳斯达克代码：TENX - 获取免费报告）最近一次发布季度财报是在 11 月 12 日星期三。这家专业制药公司报告本季度每股收益（EPS）为-0.40 美元，超出分析师一致预期的-1.33 美元，超出幅度为 0.93 美元。分析师平均预计 Tenax Therapeutics, Inc.在当前财政年度的每股收益为-0.88 美元。</p>
<h2>分析师设定新的目标价</h2>
<p>TENX 已成为几份研究分析报告的主题。Guggenheim 在 8 月 14 日的研究报告中将 Tenax Therapeutics 的目标价从 15.00 美元下调至 14.00 美元，并对该股票给予 “买入” 评级。华尔街 Zen 在 10 月 25 日的报告中将 Tenax Therapeutics 的股票评级上调至 “卖出”。Weiss Ratings 在周一的研究报告中重申了对 Tenax Therapeutics 股票的 “卖出（e+）” 评级。最后，Piper Sandler 在 9 月 8 日的研究报告中开始覆盖 Tenax Therapeutics 的股票，给予 “增持” 评级，并设定 20.00 美元的目标价。三位分析师对该股票给予 “买入” 评级，一位分析师给予 “卖出” 评级。根据 MarketBeat.com 的数据，该公司目前的平均评级为 “适度买入”，共识目标价为 18.00 美元。</p>
<p><strong>获取我们关于 TENX 的最新股票报告</strong></p>
<h2>机构投资者对 Tenax Therapeutics 的看法</h2>
<p>机构投资者和对冲基金最近增加或减少了对该股票的持仓。Virtu Financial LLC 在第三季度购买了 Tenax Therapeutics 的新股份，价值约 92,000 美元。Citadel Advisors LLC 在第三季度将其在 Tenax Therapeutics 的持股增加了 318.1%。Citadel Advisors LLC 现在拥有 43,253 股这家专业制药公司的股票，价值 329,000 美元，此前在上个季度又购买了 32,908 股。ADAR1 Capital Management LLC 在第一季度将其在 Tenax Therapeutics 的持股增加了 98.1%。ADAR1 Capital Management LLC 现在拥有 68,741 股这家专业制药公司的股票，价值 450,000 美元，此前又购买了 34,048 股。Woodline Partners LP 在第三季度收购了 Tenax Therapeutics 的新股份，价值约 671,000 美元。最后，Millennium Management LLC 在第三季度将其在 Tenax Therapeutics 的持股增加了 34.2%。Millennium Management LLC 现在拥有 313,712 股这家专业制药公司的股票，价值 2,387,000 美元，此前在上个季度又收购了 79,998 股。目前，1.67% 的股票由机构投资者和对冲基金持有。</p>
<h2>关于 Tenax Therapeutics</h2>
<p>（获取免费报告）</p>
<p>Tenax Therapeutics, Inc.开发和商业化含有伊马替尼的药物产品，用于治疗美国的肺动脉高压。该公司开发的 TNX-101（IV）、TNX-102 和 TNX-103（左西孟旦）已完成针对与心力衰竭伴有保留射血分数相关的肺动脉高压患者的二期临床试验；以及 TNX-201（伊马替尼），一种用于治疗慢性髓性白血病的酪氨酸激酶抑制剂。</p>
<h2>精选故事</h2>
<ul>
<li>我们更喜欢的五只股票超过 Tenax Therapeutics</li>
<li>使用 MarketBeat 股息税计算器</li>
<li>Rocket Lab 的大反弹？分析师认为下跌是一个机会</li>
<li>制造业股票投资</li>
<li>Meta 的人工智能时刻？新的 SAM 3 模型让华尔街变得乐观</li>
<li>这些液化天然气股票准备迎来反弹吗？</li>
<li>Snowflake 股票：聪明投资者正在购买的下跌</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VEVOWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VEVOWA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Tenax Therapeutics 吗？</h2>
<p>在考虑 Tenax Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街评级最高和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Tenax Therapeutics 并不在名单上。</p>
<p>虽然 Tenax Therapeutics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

TENX

<p>Tenax Therapeutics 的内部人士 Stuart Rich 以每股 9.20 美元的价格购买了 2,500 股，总计 23,000 美元。此交易已向 SEC 披露，显著增加了他的持股比例。最近的交易包括以 9.08 美元购买 1,500 股和以 9.01 美元购买 1,000 股。TENX 股价上涨 3.2% 至 9.65 美元。分析师的评级不一，普遍目标价为 18.00 美元。机构投资者已调整其持股比例，Citadel Advisors 和 Millennium Management 的增持尤为显著</p>

<p>Tenax Therapeutics, Inc. (NASDAQ:TENX - Get Free Report) insider Stuart Rich bought 2,500 shares of the business's stock in a transaction dated Thursday, December 4th. The shares were bought at an average cost of $9.20 per share, for a total transaction of $23,000.00. Following the completion of the transaction, the insider directly owned 2,500 shares of the company's stock, valued at $23,000. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link.</p>
<div class="lb-trans"><p>Tenax Therapeutics, Inc.（纳斯达克代码：TENX - 获取免费报告）内部人士 Stuart Rich 于 12 月 4 日星期四购买了 2,500 股该公司的股票。每股平均购买价格为 9.20 美元，总交易额为 23,000.00 美元。交易完成后，该内部人士直接持有 2,500 股公司股票，价值 23,000 美元。这笔交易代表了他们对该股票的持有量增加了∞。该交易已在向 SEC 提交的文件中披露，文件可通过此链接获取。</p>
</div><p>Stuart Rich also recently made the following trade(s):</p>
<div class="lb-trans"><p>Stuart Rich 最近还进行了以下交易：</p>
</div><ul>
<li>On Wednesday, December 3rd, Stuart Rich purchased 1,500 shares of Tenax Therapeutics stock. The stock was bought at an average price of $9.08 per share, with a total value of $13,620.00.</li>
<li>On Tuesday, December 2nd, Stuart Rich acquired 1,000 shares of Tenax Therapeutics stock. The shares were bought at an average price of $9.01 per share, for a total transaction of $9,010.00.</li>
</ul>
<div class="lb-trans"><ul>
<li>在 12 月 3 日星期三，Stuart Rich 购买了 1,500 股 Tenax Therapeutics 的股票。股票的平均购买价格为每股 9.08 美元，总价值为 13,620.00 美元。</li>
<li>在 12 月 2 日星期二，Stuart Rich 收购了 1,000 股 Tenax Therapeutics 的股票。每股平均购买价格为 9.01 美元，总交易额为 9,010.00 美元。</li>
</ul>
</div><p>Get <strong>Tenax Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Tenax Therapeutics</strong> 的提醒：</p>
</div><h2>Tenax Therapeutics Trading Up 3.2%</h2>
<div class="lb-trans"><h2>Tenax Therapeutics 股价上涨 3.2%</h2>
</div><p>Shares of TENX traded up $0.30 during midday trading on Friday, hitting $9.65. The stock had a trading volume of 168,431 shares, compared to its average volume of 50,192. The business has a 50-day simple moving average of $7.66 and a two-hundred day simple moving average of $6.58. The firm has a market cap of $60.25 million, a P/E ratio of -8.54 and a beta of 1.55. Tenax Therapeutics, Inc. has a fifty-two week low of $4.63 and a fifty-two week high of $9.91.</p>
<div class="lb-trans"><p>在周五的午盘交易中，TENX 的股价上涨了 0.30 美元，达到了 9.65 美元。该股票的交易量为 168,431 股，而其平均交易量为 50,192 股。该公司的 50 日简单移动平均线为 7.66 美元，200 日简单移动平均线为 6.58 美元。该公司的市值为 6025 万美元，市盈率为-8.54，贝塔值为 1.55。Tenax Therapeutics, Inc.的 52 周最低价为 4.63 美元，52 周最高价为 9.91 美元。</p>
</div><p>Tenax Therapeutics (NASDAQ:TENX - Get Free Report) last posted its quarterly earnings data on Wednesday, November 12th. The specialty pharmaceutical company reported ($0.40) EPS for the quarter, topping analysts' consensus estimates of ($1.33) by $0.93. On average, analysts expect that Tenax Therapeutics, Inc. will post -0.88 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Tenax Therapeutics（纳斯达克代码：TENX - 获取免费报告）最近一次发布季度财报是在 11 月 12 日星期三。这家专业制药公司报告本季度每股收益（EPS）为-0.40 美元，超出分析师一致预期的-1.33 美元，超出幅度为 0.93 美元。分析师平均预计 Tenax Therapeutics, Inc.在当前财政年度的每股收益为-0.88 美元。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新的目标价</h2>
</div><p>TENX has been the topic of several research analyst reports. Guggenheim lowered their target price on Tenax Therapeutics from $15.00 to $14.00 and set a &#34;buy&#34; rating on the stock in a research note on Thursday, August 14th. Wall Street Zen upgraded shares of Tenax Therapeutics to a &#34;sell&#34; rating in a report on Saturday, October 25th. Weiss Ratings reiterated a &#34;sell (e+)&#34; rating on shares of Tenax Therapeutics in a research note on Monday. Finally, Piper Sandler began coverage on shares of Tenax Therapeutics in a research report on Monday, September 8th. They issued an &#34;overweight&#34; rating and a $20.00 target price for the company. Three analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $18.00.</p>
<div class="lb-trans"><p>TENX 已成为几份研究分析报告的主题。Guggenheim 在 8 月 14 日的研究报告中将 Tenax Therapeutics 的目标价从 15.00 美元下调至 14.00 美元，并对该股票给予 “买入” 评级。华尔街 Zen 在 10 月 25 日的报告中将 Tenax Therapeutics 的股票评级上调至 “卖出”。Weiss Ratings 在周一的研究报告中重申了对 Tenax Therapeutics 股票的 “卖出（e+）” 评级。最后，Piper Sandler 在 9 月 8 日的研究报告中开始覆盖 Tenax Therapeutics 的股票，给予 “增持” 评级，并设定 20.00 美元的目标价。三位分析师对该股票给予 “买入” 评级，一位分析师给予 “卖出” 评级。根据 MarketBeat.com 的数据，该公司目前的平均评级为 “适度买入”，共识目标价为 18.00 美元。</p>
</div><p><strong>Get Our Latest Stock Report on TENX</strong></p>
<div class="lb-trans"><p><strong>获取我们关于 TENX 的最新股票报告</strong></p>
</div><h2>Institutional Investors Weigh In On Tenax Therapeutics</h2>
<div class="lb-trans"><h2>机构投资者对 Tenax Therapeutics 的看法</h2>
</div><p>Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Virtu Financial LLC bought a new stake in Tenax Therapeutics during the third quarter valued at about $92,000. Citadel Advisors LLC raised its stake in Tenax Therapeutics by 318.1% during the 3rd quarter. Citadel Advisors LLC now owns 43,253 shares of the specialty pharmaceutical company's stock valued at $329,000 after purchasing an additional 32,908 shares during the last quarter. ADAR1 Capital Management LLC increased its holdings in shares of Tenax Therapeutics by 98.1% during the 1st quarter. ADAR1 Capital Management LLC now owns 68,741 shares of the specialty pharmaceutical company's stock worth $450,000 after purchasing an additional 34,048 shares during the period. Woodline Partners LP acquired a new stake in Tenax Therapeutics during the third quarter worth about $671,000. Finally, Millennium Management LLC raised its holdings in Tenax Therapeutics by 34.2% in the 3rd quarter. Millennium Management LLC now owns 313,712 shares of the specialty pharmaceutical company's stock valued at $2,387,000 after acquiring an additional 79,998 shares in the last quarter. 1.67% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>机构投资者和对冲基金最近增加或减少了对该股票的持仓。Virtu Financial LLC 在第三季度购买了 Tenax Therapeutics 的新股份，价值约 92,000 美元。Citadel Advisors LLC 在第三季度将其在 Tenax Therapeutics 的持股增加了 318.1%。Citadel Advisors LLC 现在拥有 43,253 股这家专业制药公司的股票，价值 329,000 美元，此前在上个季度又购买了 32,908 股。ADAR1 Capital Management LLC 在第一季度将其在 Tenax Therapeutics 的持股增加了 98.1%。ADAR1 Capital Management LLC 现在拥有 68,741 股这家专业制药公司的股票，价值 450,000 美元，此前又购买了 34,048 股。Woodline Partners LP 在第三季度收购了 Tenax Therapeutics 的新股份，价值约 671,000 美元。最后，Millennium Management LLC 在第三季度将其在 Tenax Therapeutics 的持股增加了 34.2%。Millennium Management LLC 现在拥有 313,712 股这家专业制药公司的股票，价值 2,387,000 美元，此前在上个季度又收购了 79,998 股。目前，1.67% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>About Tenax Therapeutics</h2>
<div class="lb-trans"><h2>关于 Tenax Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.</p>
<div class="lb-trans"><p>Tenax Therapeutics, Inc.开发和商业化含有伊马替尼的药物产品，用于治疗美国的肺动脉高压。该公司开发的 TNX-101（IV）、TNX-102 和 TNX-103（左西孟旦）已完成针对与心力衰竭伴有保留射血分数相关的肺动脉高压患者的二期临床试验；以及 TNX-201（伊马替尼），一种用于治疗慢性髓性白血病的酪氨酸激酶抑制剂。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Tenax Therapeutics</li>
<li>Using the MarketBeat Dividend Tax Calculator</li>
<li>Rocket Lab’s Big Rebound? Analysts Suggest the Dip's a Gift</li>
<li>Manufacturing Stocks Investing</li>
<li>Meta’s AI Moment? New SAM 3 Model Has Wall Street Turning Bullish</li>
<li>Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?</li>
<li>Snowflake Stock: The Dip That Smart Investors Are Buying Right Now</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更喜欢的五只股票超过 Tenax Therapeutics</li>
<li>使用 MarketBeat 股息税计算器</li>
<li>Rocket Lab 的大反弹？分析师认为下跌是一个机会</li>
<li>制造业股票投资</li>
<li>Meta 的人工智能时刻？新的 SAM 3 模型让华尔街变得乐观</li>
<li>这些液化天然气股票准备迎来反弹吗？</li>
<li>Snowflake 股票：聪明投资者正在购买的下跌</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VEVOWA" alt="" original-src="https://www.marketbeat.com/scripts/InsiderTradesChart.ashx?Prefix=NASDAQ&amp;Symbol=TENX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Tenax Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Tenax Therapeutics 吗？</h2>
</div><p>Before you consider Tenax Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Tenax Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tenax Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街评级最高和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Tenax Therapeutics 并不在名单上。</p>
</div><p>While Tenax Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Tenax Therapeutics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Tenax Therapeutics (NASDAQ:TENX) 的内部人士 Stuart Rich 购买了 2,500 股股票